Provided by Tiger Trade Technology Pte. Ltd.

Ocular Therapeutix

8.51
-0.1150-1.33%
Post-market: 8.40-0.1050-1.23%19:39 EDT
Volume:1.17M
Turnover:9.95M
Market Cap:1.86B
PE:-5.87
High:8.71
Open:8.66
Low:8.43
Close:8.62
52wk High:16.44
52wk Low:6.23
Shares:218.91M
Float Shares:184.00M
Volume Ratio:0.60
T/O Rate:0.63%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4491
EPS(LYR):-1.4203
ROE:-68.55%
ROA:-32.88%
PB:3.20
PE(LYR):-5.99

Loading ...

Ocular Therapeutix Grants New Hires Options for 34,700 Shares at $9.66 Each

Reuters
·
Jul 10

Ocular Therapeutix™ Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Jul 10

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jul 10

OCUL’s OTX-TKI Extension Study: Long-Term Safety Data Could Shape Wet AMD Market

TIPRANKS
·
Jul 02

Does Broad Russell Value Index Inclusion Reshape the Bull Case for Ocular Therapeutix (OCUL)?

Simply Wall St.
·
Jul 01

Ocular Therapeutix to Present at ASRS Annual Meeting

Reuters
·
Jul 01

Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences

GlobeNewswire
·
Jul 01

Ocular Therapeutix is Maintained at Buy by Chardan Capital

Dow Jones
·
Jun 25

Chardan Raises Price Target on Ocular Therapeutix to $23 From $21, Keeps Buy Rating

MT Newswires Live
·
Jun 25

Ocular Therapeutix grants new SVP inducement awards of 85,000 stock options, 28,000 RSUs

Reuters
·
Jun 23

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jun 23

FDA Alignment on Axpaxli and New CFO Might Change The Case For Investing In Ocular Therapeutix (OCUL)

Simply Wall St.
·
Jun 22

Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF) and Ocular Therapeutix (OCUL)

TIPRANKS
·
Jun 22

Analysts Are Bullish on These Healthcare Stocks: NovoCure (NVCR), Ocular Therapeutix (OCUL)

TIPRANKS
·
Jun 22

Ocular Therapeutix, Inc. : H.c. Wainwright Raises Target Price to $25 From $21

THOMSON REUTERS
·
Jun 18

Ocular Therapeutix Is Maintained at Outperform by Baird

Dow Jones
·
Jun 18

Ocular Therapeutix price target raised to $30 from $24 at Baird

TIPRANKS
·
Jun 18

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jun 18

Ocular Therapeutix Says FDA Aligned on Application for Axpaxli

Dow Jones
·
Jun 17

Ocular Therapeutix trading resumes

TIPRANKS
·
Jun 17